Zevra Therapeutics
ZVRA
83 hedge funds and large institutions have $45.4M invested in Zevra Therapeutics in 2022 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 23 increasing their positions, 21 reducing their positions, and 12 closing their positions.
67% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 12
8% more funds holding
Funds holding: 77 → 83 (+6)
5.1% more ownership
Funds ownership: 20.64% → 25.74% (+5.1%)
10% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 21
1% more call options, than puts
Call options by funds: $6.61M | Put options by funds: $6.54M
28% less capital invested
Capital invested by funds: $63.3M → $45.4M (-$17.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.04M |
| 2 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
+$1.62M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.52M |
| 4 |
Renaissance Technologies
New York
|
+$1.03M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$952K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
SG3 Management
Dorado,
Puerto Rico
|
-$327K |
| 2 |
MTIM
Marathon Trading Investment Management
Radnor,
Pennsylvania
|
-$295K |
| 3 |
Goldman Sachs
New York
|
-$246K |
| 4 |
Belvedere Trading
Chicago,
Illinois
|
-$220K |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$212K |
ZVRA Hedge Fund Activity: Q1 2022 in Review
83 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q1 2022, worth a combined $45.4M — down 28% from $63.3M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new ZVRA positions and 12 closed out — a net gain of 8 holders — while 23 added to existing stakes and 21 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $2.04M. The largest seller was SG3 Management, exiting entirely with an estimated $327K sold.
- 83 institutional investors held Zevra Therapeutics (ZVRA) as of Q1 2022, up from 77 in Q4 2021.
- Funds reported $45.4M of Zevra Therapeutics stock for Q1 2022, down 28% quarter-over-quarter.
- 20 funds opened new Zevra Therapeutics positions in Q1 2022 and 12 closed out, a net change of +8 holders.
- The largest Zevra Therapeutics buyer in Q1 2022 was Millennium Management, an estimated $2.04M added.
- The largest Zevra Therapeutics seller in Q1 2022 was SG3 Management, an estimated $327K sold.
Based on aggregated 13F filings for Q1 2022.